Core Insights - Dr. Reddy's Laboratories Limited (RDY) reported Q3 fiscal 2026 earnings of 16 cents per American Depositary Share (ADS), matching the Zacks Consensus Estimate, but down from 19 cents per ADS in the same quarter last year [1][5] - Revenues increased by 4.4% year over year to $971 million, but fell short of the Zacks Consensus Estimate of $978 million, primarily due to lower growth in global generics revenues [1][5] Revenue Breakdown - Global Generics revenues reached INR 79.1 billion, reflecting a 7% year-over-year increase, driven by growth in key markets and favorable foreign exchange movements, although North America Generics saw a decline [2][5] - Pharmaceutical Services & Active Ingredients (PSAI) revenues totaled INR 8 billion, down 2% year over year due to lower volume uptake in the active pharmaceutical ingredient (API) business [6] - Revenues in the Others segment were INR 0.1 billion, a significant decline of 92% year over year [6] North America Performance - North America segment revenues decreased by 12% due to lower sales of lenalidomide and increased price erosion in key products [3][5] - As of December 31, 2025, there were 73 generic filings pending FDA approval, including 71 abbreviated new drug applications (ANDAs) and two new drug applications, with 43 of the ANDAs being Para IVs [3] Margin and Expenses - Gross margin fell by 505 basis points year over year to 53.6%, attributed to lower lenalidomide sales, price erosion, adverse product mix in PSAI, and one-time provisions related to new Labor Codes in India [7][5] - Research and development (R&D) expenses were $68 million, down 8% year over year, primarily due to reduced spending in biosimilars [8] - Selling, general and administrative expenses rose to $300 million, a 12% increase year over year, driven by investments in branded franchises and adverse foreign exchange movements [9] Strategic Developments - Dr. Reddy's gained approval for AVT03, a proposed biosimilar to Amgen's Prolia and Xgeva, in the EU and the UK, and launched the product in Germany in December 2025 [12] - The company signed a strategic collaboration with Immutep to develop and commercialize the investigational immuno-oncology therapy eftilagimod alfa (efti) outside major markets, involving a $20 million upfront payment and potential milestone payments of up to $349.5 million [17][18]